XRCC1基因多态性作为接受放化疗头颈癌患者生物标志物的评估
这项前瞻性队列研究纳入101例接受同步放化疗的III至IVB期头颈鳞癌患者,比较XRCC1 Arg194Trp野生型与多态性变异者的临床结局。多态性变异者≥2级口腔黏膜炎、皮炎和喉部毒性发生率显著更高,2年无进展生存和总生存有改善趋势但未达统计学显著。
要点
- 多态性变异者≥2级口腔黏膜炎发生率为35.8% versus 野生型16.0%(OR 2.91,95%CI 1.13-7.46,P=.023)。
- 多态性变异者皮炎发生率为30.7% versus 野生型8.0%(OR 5.076,95%CI 1.62-15.8,P=.003)。
- 多态性变异者喉部毒性发生率为25.6% versus 野生型6.4%(OR 5,95%CI 1.44-17.54,P=.006)。
核心结论
- 接受同步放化疗的XRCC1多态性变异头颈鳞癌患者急性放疗不良反应显著增加,与野生型相比无进展生存可能有改善趋势。
研究设计与样本
- 前瞻性队列研究,纳入101例18岁及以上、III至IVB期、Karnofsky体能状态评分≥80且适合同步放化疗的口腔、咽和喉头颈鳞癌患者。
- 通过聚合酶链反应提取DNA,采用设计限制性片段长度多态性法检测XRCC1基因多态性,分为野生型与多态性变异(Arg194Trp CT和TT)。
- 放疗采用常规平行对穿侧野和下颈前野,同步每周顺铂35 mg/m2。
- 急性毒性按放射治疗肿瘤学组标准分级,治疗反应按世界卫生组织标准评估,总生存和无进展生存采用Kaplan-Meier法估计。
主要发现
- 101例患者中62例为野生型,39例为多态性变异。
- 多态性变异者≥2级口腔黏膜炎发生率为35.8% versus 野生型16.0%(OR 2.91,95%CI 1.13-7.46,P=.023)。
- 多态性变异者皮炎发生率为30.7% versus 野生型8.0%(OR 5.076,95%CI 1.62-15.8,P=.003)。
- 多态性变异者喉部毒性发生率为25.6% versus 野生型6.4%(OR 5,95%CI 1.44-17.54,P=.006)。
- 多态性变异者 versus 野生型完全缓解率为76.9% versus 56.0%(P=.209);中位随访21个月时,2年无进展生存率为57.0% versus 42.2%(P=.077),2年总生存率为73.0% versus 55.5%(P=.143)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the correlation of the x-ray repair cross complementing gene 1 (XRCC1) Arg194Trp polymorphism with clinical outcomes in head and neck squamous cell carcinoma (HNSCC) patients treated with concurrent chemoradiation therapy (CCRT). METHODS AND MATERIALS: In this prospective cohort study, we included 101 patients with HNSCC (oral cavity, pharynx, and larynx) who were aged ≥ 18 years, had stage III to IVB disease, had a Karnofsky Performance Status ≥ 80, and were deemed fit for CCRT. DNA extraction was done through polymerase chain reaction, and the genotypes of XRCC1 polymorphism were detected using designed restriction fragment length polymorphism. The genetic polymorphisms were classified into wild and polymorphic variants (Arg194Trp CT and TT). Radiation therapy was delivered with conventional parallel opposed lateral and low anterior neck fields with concurrent weekly cisplatin, 35 mg/m2. Acute toxicity was graded per Radiation Therapy Oncology Group criteria, and treatment response was assessed per World Health Organization criteria. Overall survival and progression-free survival (PFS) were estimated using the Kaplan-Meier method. RESULTS: Of the patients, 62 had the wild type and 39 had polymorphic variants. Patients with polymorphic variants had higher rates of grade > 2 oral mucositis, with 35.8% versus 16.0% (odds ratio [OR], 2.91; 95% confidence interval [CI], 1.13-7.46; P = .023); dermatitis, with 30.7% versus 8.0% (OR, 5.076; 95% CI, 1.62-15.8; P = .003); and laryngeal toxicity, with 25.6% versus 6.4% (OR, 5; 95% CI, 1.44-17.54; P = .006). Complete response rates in polymorphic versus wild variants were 76.9% versus 56.0% (P = .209). At a median follow-up of 21 months, the 2-year PFS and overall survival rates for patients with polymorphic versus wild variants were 57.0% versus 42.2% (P = .077) and 73.0% versus 55.5% (P = .143), respectively. CONCLUSIONS: Polymorphic variant XRCC1 HNSCC patients treated with CCRT have significantly increased acute radiation morbidities and may have a trend toward better PFS in comparison with the wild variant.
引用
- Nanda SS, Gandhi AK, Rastogi M, et al. Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29893275. doi:10.1016/j.ijrobp.2018.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。